January 7, VISEN Pharmaceuticals announced that it had submitted TransCon CNP (TransCon C-type natri
더 읽어보세요 2021-02-08뉴스 목록
VISEN Pharmaceutical's TransCon C-type natriuretic peptide Phase II clinical trial application approved in China
Progress in the development of new and efficient diabetes treatment drugs
Recently, Wang Junfeng's research team from Hefei Institute of Material Science, Chinese Academy
더 읽어보세요 2021-01-19
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S.
더 읽어보세요 2020-12-22
Merck's new HIV drug Pedro (Doravirin) was approved in China
Merck announced recentlythat its new HIV drug Pedro (doravirin tablets) has been officially approved
더 읽어보세요 2020-12-08
FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis
Pfizer announced that the U.S. Food and Drug Administration (FDA) accepted for filing and granted Pr
더 읽어보세요 2020-11-02
ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shion
더 읽어보세요 2020-10-18
European Commission Grants Marketing Authorization for Jyseleca® ▼ (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis
Gilead Sciences and Galapagos NV today announced that the European Commission (EC) has granted marke
더 읽어보세요 2020-09-27
Janssen Announces European Commission Decision for Expanded Use of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL)
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Comm
더 읽어보세요 2020-09-09
PIQRAY® is approved and now available in Canada as the first and only treatment specifically for patients with a PIK3CA mutation in HR-positive, HER2-negative advanced breast cancer
Approval is based on results from SOLAR-1, where PIQRAY®in combination with fulvestrant nearly doubl
더 읽어보세요 2020-08-20
Gastrointestinal stromal tumor (GIST) targeted new drugs! Avapritinib will be approved in the EU in September
Blueprint Medicines announced that the European Medicines Agency (EMA) Committee for Medicinal Produ
더 읽어보세요 2020-07-29